One of the most dynamic outperformers so far this year on the OTC is clearly Predictive Technology Group Inc (OTCMKTS:PRED). We profiled the story with strong support about a 3 weeks and 20% ago. And it keeps on moving into a parabolic mode to the upside as the crowd starts to appreciate the story. To further build out the narrative, the company just announced that Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health.
According to the release, “in this newly created position, he will provide critical medical affairs support for the women’s health clinical franchise. Dr. Rabin has more than 25 years of experience in women’s healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.”
Predictive Technology Group Inc (OTCMKTS:PRED) promulgates itself as a company that, together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/human cells, tissues, and human cellular and tissue-based products (HCT/Ps).
The company operates through two segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics and Therapeutics. It offers ARTguide, a genetic diagnostic and prognostic test for women experiencing infertility as a result of endometriosis and other health concerns; and regenerative medicine products, including AmnioCyteT, AmnioCyte PlusT, PolyCyteT, and CoreCyteT.
The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.
According to company materials, “Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.”
Find out when $PRED reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, PRED just announced that Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health.
We’ve witnessed 65% added to share values of the stock over the past month of action. What’s more, the stock has registered increased average transaction volume recently, with the past month seeing 120% beyond its prior sustained average level.
“We welcome Dr. Rabin to the Predictive team to support our goal of commercializing our innovative, genetic-based diagnostics that are initially focus on human infertility and women’s health,” said Bradley Robinson, CEO of Predictive Technology Group. “Dr. Rabin is highly accomplished in launching pharmaceutical and diagnostic products at Fortune 500 companies. His experience and commitment to delivering improved, more comprehensive healthcare to patients will be of tremendous assistance in supporting our mission of employing advanced molecular diagnostics to prevent or eliminate disease for generations to come.”
Currently trading at a market capitalization of $1.48B, PRED has a store ($1.8M) of cash on the books, which stands against about $11.9M in total current liabilities. One should also note that debt has been growing over recent quarters. PRED is pulling in trailing 12-month revenues of $37.2M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 166.9%. As more color becomes clear on the name, we will review the situation and update our take. Sign-up for continuing coverage on shares of $PRED stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $PRED, either long or short, and we have not been compensated for this article.